Recurrent Breast Cancer Terminated Phase 2 Trials for Tanespimycin (DB05134)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00096109Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast CancerTreatment